Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C20H16N4O2S |
| Molecular Weight | 376.432 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C(C)=O)C1=CC=CC(=C1)C2=CC=NC3=C(C=NN23)C(=O)C4=CC=CS4
InChI
InChIKey=CBIAWPMZSFFRGN-UHFFFAOYSA-N
InChI=1S/C20H16N4O2S/c1-13(25)23(2)15-6-3-5-14(11-15)17-8-9-21-20-16(12-22-24(17)20)19(26)18-7-4-10-27-18/h3-12H,1-2H3
| Molecular Formula | C20H16N4O2S |
| Molecular Weight | 376.432 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including:
http://adisinsight.springer.com/drugs/800010511
https://en.wikipedia.org/wiki/Indiplon
Curator's Comment: description was created based on several sources, including:
http://adisinsight.springer.com/drugs/800010511
https://en.wikipedia.org/wiki/Indiplon
Indiplon is a nonbenzodiazepine, hypnotic sedative that was proposed for the treatment of insomnia. It is a high-affinity allosteric potentiator of GABAA responses that demonstrates preference for α1 subunit-containing GABAA receptors. There is minimal potential for adverse effects, residual daytime sedation, tolerance, respiratory depression. The simultaneous administration of indiplon and alcohol did not result in any significant pharmacokinetic changes. There is little risk of pharmacokinetic interaction between indiplon and any co-administered drugs. Developer (Neurocrine) decided to discontinue all clinical and marketing development of Indiplon in the United States.
CNS Activity
Approval Year
Doses
| Dose | Population | Adverse events |
|---|---|---|
20 mg 1 times / day multiple, oral (unknown) Highest studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy n = 91 Health Status: unhealthy Condition: insomnia Sex: M+F Food Status: UNKNOWN Population Size: 91 Sources: |
Other AEs: Somnolence, Headache... |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Headache | 6.7% | 20 mg 1 times / day multiple, oral (unknown) Highest studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy n = 91 Health Status: unhealthy Condition: insomnia Sex: M+F Food Status: UNKNOWN Population Size: 91 Sources: |
| Somnolence | 7.8% | 20 mg 1 times / day multiple, oral (unknown) Highest studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy n = 91 Health Status: unhealthy Condition: insomnia Sex: M+F Food Status: UNKNOWN Population Size: 91 Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Gaboxadol: in vitro interaction studies with benzodiazepines and ethanol suggest functional selectivity. | 2003 Apr 25 |
|
| Rotarod studies in the rat of the GABAA receptor agonist gaboxadol: lack of ethanol potentiation and benzodiazepine cross-tolerance. | 2003 Dec 15 |
|
| Neurocrine Biosciences, Inc. Soporific science. | 2003 May |
|
| Sleeping pills without regrets. They've long been the risky quick fixes of sleep medicine. Soon some sleeping pills may be sold as long-term solutions. | 2004 Aug |
|
| Gateways to clinical trials. | 2004 Dec |
|
| Characterization of the interaction of indiplon, a novel pyrazolopyrimidine sedative-hypnotic, with the GABAA receptor. | 2004 Nov |
|
| Sleep disturbances, psychiatric disorders, and psychotropic drugs. | 2005 |
|
| Synthesis, pharmacology and molecular modeling of N-substituted 2-phenyl-indoles and benzimidazoles as potent GABA(A) agonists. | 2006 Aug |
|
| Gateways to clinical trials. | 2006 Dec |
|
| Efficacy and tolerability of modified-release indiplon in elderly patients with chronic insomnia: results of a 2-week double-blind, placebo-controlled trial. | 2006 Jul 15 |
|
| Gateways to clinical trials. | 2006 Jul-Aug |
|
| The new cancer fighter (and other hot drugs on the way). | 2006 Mar 20 |
|
| Gateways to clinical trials. | 2006 Sep |
|
| Relative abuse liability of indiplon and triazolam in humans: a comparison of psychomotor, subjective, and cognitive effects. | 2007 Aug |
|
| Indiplon in the treatment of sleep disorders. | 2007 Dec |
|
| Efficacy and safety of as-needed, post bedtime dosing with indiplon in insomnia patients with chronic difficulty maintaining sleep. | 2007 Dec |
|
| New perspectives for the treatment of disorders of sleep and arousal. | 2007 Jul |
|
| Radiosynthesis and biological evaluation of an 18F-labeled derivative of the novel pyrazolopyrimidine sedative-hypnotic agent indiplon. | 2007 Jul |
|
| Lack of generalisation between the GABAA receptor agonist, gaboxadol, and allosteric modulators of the benzodiazepine binding site in the rat drug discrimination procedure. | 2007 Jul |
|
| [New hypnotics: perspectives from sleep physiology]. | 2007 Jul-Aug |
|
| Long-term nightly treatment with indiplon in adults with primary insomnia: results of a double-blind, placebo-controlled, 3-month study. | 2007 Jun |
|
| Will insomnia treatments produce overall cost savings to commercial managed-care plans? A predictive analysis in the United States. | 2007 Jun |
|
| Indiplon: the development of a novel therapy for the treatment of sleep onset and sleep maintenance insomnia. | 2007 Jun |
|
| Post-bedtime dosing with indiplon in adults and the elderly: results from two placebo-controlled, active comparator crossover studies in healthy volunteers. | 2008 Mar |
|
| Diagnosis and treatment of chronic insomnia. | 2010 Apr |
|
| The societal costs of insomnia. | 2010 Dec 20 |
Sample Use Guides
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:54:45 GMT 2023
by
admin
on
Fri Dec 15 15:54:45 GMT 2023
|
| Record UNII |
8BT63DA42E
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C28197
Created by
admin on Fri Dec 15 15:54:45 GMT 2023 , Edited by admin on Fri Dec 15 15:54:45 GMT 2023
|
||
|
NCI_THESAURUS |
C29756
Created by
admin on Fri Dec 15 15:54:45 GMT 2023 , Edited by admin on Fri Dec 15 15:54:45 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
CHEMBL262075
Created by
admin on Fri Dec 15 15:54:45 GMT 2023 , Edited by admin on Fri Dec 15 15:54:45 GMT 2023
|
PRIMARY | |||
|
6450813
Created by
admin on Fri Dec 15 15:54:45 GMT 2023 , Edited by admin on Fri Dec 15 15:54:45 GMT 2023
|
PRIMARY | |||
|
m6254
Created by
admin on Fri Dec 15 15:54:45 GMT 2023 , Edited by admin on Fri Dec 15 15:54:45 GMT 2023
|
PRIMARY | Merck Index | ||
|
DTXSID80186270
Created by
admin on Fri Dec 15 15:54:45 GMT 2023 , Edited by admin on Fri Dec 15 15:54:45 GMT 2023
|
PRIMARY | |||
|
8200
Created by
admin on Fri Dec 15 15:54:45 GMT 2023 , Edited by admin on Fri Dec 15 15:54:45 GMT 2023
|
PRIMARY | |||
|
300000034229
Created by
admin on Fri Dec 15 15:54:45 GMT 2023 , Edited by admin on Fri Dec 15 15:54:45 GMT 2023
|
PRIMARY | |||
|
DB12590
Created by
admin on Fri Dec 15 15:54:45 GMT 2023 , Edited by admin on Fri Dec 15 15:54:45 GMT 2023
|
PRIMARY | |||
|
8BT63DA42E
Created by
admin on Fri Dec 15 15:54:45 GMT 2023 , Edited by admin on Fri Dec 15 15:54:45 GMT 2023
|
PRIMARY | |||
|
325715-02-4
Created by
admin on Fri Dec 15 15:54:45 GMT 2023 , Edited by admin on Fri Dec 15 15:54:45 GMT 2023
|
PRIMARY | |||
|
Indiplon
Created by
admin on Fri Dec 15 15:54:45 GMT 2023 , Edited by admin on Fri Dec 15 15:54:45 GMT 2023
|
PRIMARY | |||
|
MM-52
Created by
admin on Fri Dec 15 15:54:45 GMT 2023 , Edited by admin on Fri Dec 15 15:54:45 GMT 2023
|
PRIMARY | |||
|
C74385
Created by
admin on Fri Dec 15 15:54:45 GMT 2023 , Edited by admin on Fri Dec 15 15:54:45 GMT 2023
|
PRIMARY | |||
|
C469870
Created by
admin on Fri Dec 15 15:54:45 GMT 2023 , Edited by admin on Fri Dec 15 15:54:45 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET->MODULATOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
